Irinotecan + CMAB009

Irinotecan + CMAB009 is a combination therapy used primarily as a second-line treatment for metastatic colorectal cancer (mCRC) in patients with wild-type KRAS. Irinotecan is a small molecule chemotherapeutic agent classified as a topoisomerase I inhibitor; it works by interfering with the DNA replication process in cancer cells, leading to cell death[3][7]. CMAB009 is a chimeric monoclonal antibody that targets the human epidermal growth factor receptor (EGFR), inhibiting EGFR-mediated signaling pathways involved in tumor cell proliferation and survival[5][8]. This combination has demonstrated superior efficacy compared to irinotecan alone in clinical trials, improving overall response rate and progression-free survival for mCRC patients[2][4][5]. Irinotecan was developed by Yakult Honsha and is widely manufactured. CMAB009 was developed by MabPharm and commercialized through partnerships such as Simcere Zaiming in China[6].

Other names

cetuximab betarecombinant anti-epidermal growth factor receptor chimeric monoclonal antibodyirinotecan hydrochloride